Literature DB >> 35446600

For Head and Neck Cancer, It Is Still Cisplatin, But How Much, How Often, and How Tolerable? New Randomized Phase III Data For the Adjuvant Setting.

D Neil Hayes1, John Patrick Gleysteen1,2, David Louis Schwartz1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35446600      PMCID： PMC9197374          DOI： 10.1200/JCO.22.00274

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   50.717


× No keyword cloud information.
  16 in total

1.  Advances in radiotherapy and implications for the next century: a historical perspective.

Authors:  Philip P Connell; Samuel Hellman
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

2.  Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.

Authors:  Maura L Gillison; Andy M Trotti; Jonathan Harris; Avraham Eisbruch; Paul M Harari; David J Adelstein; Richard C K Jordan; Weiqiang Zhao; Erich M Sturgis; Barbara Burtness; John A Ridge; Jolie Ringash; James Galvin; Min Yao; Shlomo A Koyfman; Dukagjin M Blakaj; Mohammed A Razaq; A Dimitrios Colevas; Jonathan J Beitler; Christopher U Jones; Neal E Dunlap; Samantha A Seaward; Sharon Spencer; Thomas J Galloway; Jack Phan; James J Dignam; Quynh Thu Le
Journal:  Lancet       Date:  2018-11-15       Impact factor: 79.321

3.  Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.

Authors:  Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

4.  Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).

Authors:  Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre
Journal:  Head Neck       Date:  2005-10       Impact factor: 3.147

5.  Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

Authors:  Marshall R Posner; Diane M Hershock; Cesar R Blajman; Elizabeth Mickiewicz; Eric Winquist; Vera Gorbounova; Sergei Tjulandin; Dong M Shin; Kevin Cullen; Thomas J Ervin; Barbara A Murphy; Luis E Raez; Roger B Cohen; Monica Spaulding; Roy B Tishler; Berta Roth; Rosana del Carmen Viroglio; Varagur Venkatesan; Ilya Romanov; Sanjiv Agarwala; K William Harter; Matthew Dugan; Anthony Cmelak; Arnold M Markoe; Paul W Read; Lynn Steinbrenner; A Dimitrios Colevas; Charles M Norris; Robert I Haddad
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

6.  Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial.

Authors:  Lionnel Geoffrois; Laurent Martin; Dominique De Raucourt; Xu Shan Sun; Yungan Tao; Philippe Maingon; Joëlle Buffet; Yoann Pointreau; Christian Sire; Claude Tuchais; Emmanuel Babin; Alexandre Coutte; Frédéric Rolland; Marie-Christine Kaminsky; Marc Alfonsi; Michel Lapeyre; Marie Saliou; Cédric Lafond; Eric Jadaud; Bernard Gery; Ayman Zawadi; Jean-Marc Tourani; Cédric Khoury; Anne Rose Henry; Ali Hasbini; François Guichard; Christian Borel; Nicolas Meert; Pierre Guillet; Marie-Hélène Calais; Pascal Garaud; Jean Bourhis
Journal:  J Clin Oncol       Date:  2018-07-17       Impact factor: 44.544

7.  A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer.

Authors:  Wei-Xiong Xia; Xing Lv; Hu Liang; Guo-Ying Liu; Rui Sun; Qi Zeng; Si-Wei Li; Hao-Yuan Mo; Fei Han; Dong-Hua Luo; Qing Liu; Meng-Yun Shi; Yan-Fang Ye; Jing Yang; Liang-Ru Ke; Meng-Yun Qiang; Wen-Ze Qiu; Ya-Hui Yu; Kui-Yuan Liu; Xin-Jun Huang; Wang-Zhong Li; Shu-Hui Lv; Zhuo-Chen Cai; Jing-Jing Miao; Ling Guo; Ming-Yuan Chen; Ka-Jia Cao; Lin Wang; Chong Zhao; Pei-Yu Huang; Qiu-Yan Chen; Yi-Jun Hua; Lin-Quan Tang; Chao-Nan Qian; Hai-Qiang Mai; Xiang Guo; Yan-Qun Xiang
Journal:  Clin Cancer Res       Date:  2021-06-03       Impact factor: 12.531

8.  Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).

Authors:  Robert L Ferris; Yael Flamand; Gregory S Weinstein; Shuli Li; Harry Quon; Ranee Mehra; Joaquin J Garcia; Christine H Chung; Maura L Gillison; Umamaheswar Duvvuri; Bert W O'Malley; Enver Ozer; Giovana R Thomas; Wayne M Koch; Neil D Gross; R Bryan Bell; Nabil F Saba; Miriam Lango; Eduardo Méndez; Barbara Burtness
Journal:  J Clin Oncol       Date:  2021-10-26       Impact factor: 50.717

9.  Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.

Authors:  Hisham Mehanna; Max Robinson; Andrew Hartley; Anthony Kong; Bernadette Foran; Tessa Fulton-Lieuw; Matthew Dalby; Pankaj Mistry; Mehmet Sen; Lorcan O'Toole; Hoda Al Booz; Karen Dyker; Rafael Moleron; Stephen Whitaker; Sinead Brennan; Audrey Cook; Matthew Griffin; Eleanor Aynsley; Martin Rolles; Emma De Winton; Andrew Chan; Devraj Srinivasan; Ioanna Nixon; Joanne Grumett; C René Leemans; Jan Buter; Julia Henderson; Kevin Harrington; Christopher McConkey; Alastair Gray; Janet Dunn
Journal:  Lancet       Date:  2018-11-15       Impact factor: 79.321

10.  Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial.

Authors:  Naomi Kiyota; Makoto Tahara; Junki Mizusawa; Takeshi Kodaira; Hirofumi Fujii; Tomoko Yamazaki; Hiroki Mitani; Shigemichi Iwae; Yasushi Fujimoto; Yusuke Onozawa; Nobuhiro Hanai; Takenori Ogawa; Hiroki Hara; Nobuya Monden; Eiji Shimura; Shujiro Minami; Takashi Fujii; Kaoru Tanaka; Akihiro Homma; Seiichi Yoshimoto; Nobuhiko Oridate; Koichi Omori; Tsutomu Ueda; Kenji Okami; Ichiro Ota; Kiyoto Shiga; Masashi Sugasawa; Takahiro Asakage; Yuki Saito; Shigeyuki Murono; Yasumasa Nishimura; Kenichi Nakamura; Ryuichi Hayashi
Journal:  J Clin Oncol       Date:  2022-03-01       Impact factor: 50.717
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.